SAMSUNG BIOLOGICS (207940) Stock Analysis — March 2026
Company Overview
Samsung Biologics is a leading Contract Development and Manufacturing Organization (CDMO) globally, manufacturing biopharmaceutical products in Korea, Europe, and the United States. The company operates through its CDMO and biopharmaceutical development & commercialization segments. Development services encompass late-stage discovery, cell line development, process development, analytical development, and non-GMP/CGMP manufacturing. Furthermore, it offers integrated solutions including aseptic filling, lyophilization, finished product manufacturing, storage, transportation, and regulatory support, establishing itself as a trusted partner for global pharmaceutical companies.
Key Metrics
| Metric | Value |
|---|---|
| Current Price | ₩1,569,000 (-1.44%) |
| Market Cap | ₩72.6 Trillion |
| PER | 59.91 |
| Forward PER | 41.00 |
| PBR | 9.89 |
| ROE | 17.6% |
| ROA | 9.1% |
| Operating Margin | 41.1% |
| Debt-to-Equity Ratio | 12% |
Valuation Analysis
Samsung Biologics exhibits a Price-to-Earnings Ratio (PER) of 59.91 and a Forward PER of 41.00, indicating a relatively high valuation in relation to its current and future earnings. The Price-to-Book Ratio (PBR) of 9.89 further suggests a potential overvaluation relative to its asset value. However, this premium valuation can be attributed to the significant growth potential of the biopharmaceutical CDMO industry and market expectations for the company's unique technological capabilities and extensive global manufacturing capacity. While a comparative analysis against industry averages would be beneficial, leading companies in high-growth sectors typically command higher valuations.
Growth & Profitability
Samsung Biologics demonstrates robust profitability. A Return on Equity (ROE) of 17.6% and a Return on Assets (ROA) of 9.1% highlight its efficient ability to generate profits relative to its equity and assets, respectively. Notably, an operating margin of 41.1% underscores the company's strong pricing power and operational efficiency. The net profit margin, also at a high 39.16%, indicates a structure where revenue growth directly translates into substantial profits. The company is expected to sustain its revenue and earnings growth trajectory driven by the continuous expansion of the global CDMO market and the scaling up of new manufacturing facilities.
Recent News & Issues
(No information provided)
Risk Factors
- Global Economic Downturn and Interest Rate Hikes: The biopharmaceutical industry requires substantial investment. A global economic slowdown or rising interest rates could pose challenges to R&D and manufacturing investments.
- Intensifying Competition and Technological Advancements: The CDMO market is highly competitive. The emergence of new technologies or aggressive investments by competitors could lead to shifts in market positioning.
- Changes in Regulatory Environment: Biopharmaceuticals operate under stringent regulatory frameworks. Changes in regulations across different countries can impact manufacturing and sales.
Overall Assessment
Samsung Biologics leads the biopharmaceutical CDMO market with its strong technological capabilities and global manufacturing scale. The company exhibits high profitability and efficient operational capabilities, with significant future growth potential. However, the current valuation level may present some concerns, and continuous monitoring of global economic conditions and competitive landscape changes is advisable. The company is expected to achieve concurrent growth with the expansion of the biopharmaceutical industry over the long term.
This analysis is AI-generated for reference only, not investment advice.